Phase 4 N=136 Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
Urinary Tract Diseases
Primary: Total Opioid Consumption — 16.4; 15.3 morphine equivalent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=150 TeamTRACS Pilot (CTSI)
Teamwork · Implementation
Primary: Change in Teamwork Knowledge From Baseline to 3-month Follow-up — 75.60; 74.72; 80.00; 75.00 percentage correct answers — p=.03
Phase 2 N=24 Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis
Primary Biliary Cholangitis · Primary Biliary Cirrhosis · Cholangitis
Primary: Percent Change in Alkaline Phosphatase (ALP) at Week 12 Compared to Baseline — -7.7 percent change — p==0.077
Phase 2 N=112 Randomized Study of Obicetrapib in Combination With Ezetimibe
Dyslipidemias · High Cholesterol · Hypercholesterolemia
Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]…
Phase 2 N=216 Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Papulopustular Rosacea
Primary: Co-primary Endpoint: Change From Baseline in Number of Rosacea Inflammatory Lesions — -10.0; -6.7; -9.2 lesions (rosacea inflammatory)
N/A N=12 Impact of Muscle Temperature on Muscle Growth and Breakdown: Cooling During Resistance Training
Exercise Training
Primary: RT-qPCR for Forkhead Box O3 (FOXO3a) — 1.24; 1.30 fold change — p=.609
N/A N=309 Community-based Intervention Effects on Older Adults' Physical Activity
Exercise · Physical Activity · Accidental Fall
Primary: Quantity of Physical Activity Measured Objectively — 177.9; 167.7; 185.9; 177.9 minutes per day
N/A N=35 Pilot Testing an Innovative Physical Activity Intervention for Parents Attending Their Children's Sport Practices
Physical Inactivity
Primary: Moderate to Vigorous Physical Activity (Minutes/Week) — 26.10 minutes/week
Phase 4 N=12 The Influence of Menthol Gel During Exercise With Heat
Acute Exercise · Heat Exposure
Primary: Skin Blood Flow — 131.6; 119.2 arbitrary units — p=0.742
N/A N=4 RESCU System for Robust Upper Limb Prosthesis Control
Amputation · Upper Limb
Primary: Mean Daily Prosthesis Use Duration — 3.81; 6.83 hours
N/A N=39 Clinical Evaluation of a 1060 nm Diode Laser, PEMF and Vacuum Assisted MP RF for Non-invasive Fat Reduction
Adipose Tissue Atrophy
Primary: Change in Aesthetic Appearance From Baseline — 0.97 score on a scale
N/A N=97 Hostile Interpretation Bias Training to Treat Irritability
Irritable Mood · Mood Disorders
Primary: Change in Interpretation Bias — 1.53; 0.55 units on a scale — p=<0.001
Phase 2 N=48 Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant
Bone Marrow Transplantation Recipient · Cord Blood Transplant Recipient · Hematopoietic Cell Transplantation Recipient
Primary: Number of Participants That Achieved Platelet Engraftment Greater Than 50K/ul — 3; 30 Participants
N/A N=312 CATCH-UP Vaccines: Engaged Approaches to Testing in Community/Healthcare Settings for the Underserved (COVID-19)
COVID-19 · Vaccine Refusal
Primary: Percentage of Participants Who Plan to Receive a COVID-19 Vaccine Post-intervention — 19; 24; 19; 21 Participants
Phase 2 N=291 A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Percentage of Participants Who Achieved a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24 — 20; 27; 22; 22…